Apalutamide Added to NCCN Prostate Cancer Guidelines March 12, 2018 The NCCN now lists apalutamide (Erleada) as a category 1 recommendation for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC).Read more.Source: OncLive Prostate Cancer News
The NCCN now lists apalutamide (Erleada) as a category 1 recommendation for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC).Read more.Source: OncLive
Donate Now
